Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Radium-223 after abiraterone: symptomatic skeletal events in patients with mCRPC

In patients with metastatic castration-resistant prostate cancer (mCRPC), androgen deprivation therapy can have a detrimental effect on bone health. Joe O’Sullivan, MD, of Queen’s University Belfast, Belfast, UK, brings this issue to light, highlighting the need to pay more attention to bone mineral loss in mCRPC patients receiving abiraterone therapy. Prof. O’Sullivan develops these conclusions after results from the ERA 223 trial (NCT02043678), which revealed an increased risk of bone fractures in mCRPC patients, regardless of radium-223 therapy. Speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Prof. O’Sullivan suggests the adminstration of bone health agents, such as zoledronic acid, in mCRPC patients receiving abiraterone.